Home / Peptide legality / Montana
Are peptides legal in Montana?
Montana sits in a legal gray zone for peptides: standard federal rules make FDA-approved GLP-1 medicines like Wegovy® (semaglutide) legal by prescription and leave research peptides such as BPC-157 without an ordinary clinical path, but Montana's 2025 experimental treatment law (SB 535) creates a distinctive state pathway that may allow supervised access outside normal FDA approval.
Legal status overview
Montana sits in a legal gray zone for peptides, shaped by both ordinary federal rules and an unusual state experimental-treatment pathway. Under the standard framework, FDA-approved GLP-1 medicines like Ozempic® (semaglutide) and Zepbound® (tirzepatide) are legal by prescription, while unapproved research peptides such as BPC-157 and TB-500 cannot be marketed for human use. Montana has no peptide-specific statute; its Board of Pharmacy rule ARM 24.174 applies general USP 795 and 797 compounding standards without singling out peptides. What distinguishes Montana is SB 535, signed in 2025, which licenses experimental treatment centers that may administer therapies past Phase I trials under informed consent, a Montana-specific route that could reach some peptides outside normal FDA approval.
Key points
- Montana has no statute or Board of Pharmacy bulletin specifically addressing peptides, BPC-157, TB-500, or research-use-only compounds as a distinct legal class. [1]
- Montana Board of Pharmacy administrative rule ARM 24.174 requires pharmacy personnel to follow USP compounding protocols generally and does not single out peptides. [1]
- FDA-approved GLP-1 medicines require a valid prescription from a licensed provider, following the federal requirements that apply nationwide. [1]
- Compounded semaglutide is not FDA-approved, is not a generic, and is not evaluated by the FDA, and is exempt from new-drug approval only when made for an identified patient under a valid prescription per Section 503A. [3]
- BPC-157 was in FDA Category 2 of the 503A bulk substances evaluation from 2023 and removed in April 2026, but removal is not Category 1 approval, so it remains ineligible for lawful compounding for human use. [4]
- Montana Senate Bill 535, signed in 2025, licenses experimental treatment centers through DPHHS that may recommend and administer investigational therapies past Phase I under informed consent, a Montana-specific pathway outside normal FDA approval. [2]
- SB 535 builds on Montana's 2023 right-to-try expansion that removed the terminal-illness restriction, and supporters intend the framework to reach experimental longevity therapies including some peptides. [5]
- FDA-approved growth hormone (somatropin) is prescription-only; federal law at 21 U.S.C. 333(e) makes unauthorized distribution a felony. [1]
Compound-by-compound status
| BPC-157 Gray area | Unapproved drug that cannot be marketed for human use through ordinary channels, but Montana's SB 535 experimental treatment pathway may allow supervised access outside normal FDA approval. Not lawfully sold for human use in the standard retail or pharmacy channel. |
|---|---|
| GLP-1 class (Wegovy® (semaglutide), Ozempic® (semaglutide), Zepbound® (tirzepatide), Mounjaro® (tirzepatide)) Legal By Prescription | Brand-name FDA-approved products are legal with a valid prescription. Compounded versions are not FDA-approved, are not a generic, and are not evaluated by the FDA. |
| TB-500 (thymosin beta-4 fragment) Gray area | Unapproved drug not marketable for human use in the ordinary channel; potentially reachable through Montana's experimental treatment center framework. Otherwise sold only as research-use-only material not intended for human use. |
| Growth hormone / somatropin (e.g., Genotropin® (somatropin)) Legal By Prescription | FDA-approved somatropin is prescription-only for approved indications; federal law at 21 U.S.C. 333(e) makes unauthorized distribution a felony. No Montana-specific peptide rule applies. |
Frequently asked questions
Are peptides legal in Montana?
Montana has no peptide-specific law. FDA-approved products like Wegovy® (semaglutide) are legal by prescription, unapproved research peptides such as BPC-157 cannot be marketed for human use in the ordinary channel, and a state experimental treatment pathway may reach some of them. This is information, not legal or medical advice.
What is Montana's SB 535 experimental treatment law?
Signed in 2025, SB 535 licenses experimental treatment centers through DPHHS that may recommend and administer investigational therapies past Phase I trials under informed consent, creating a Montana-specific route outside normal FDA approval.
Can I get BPC-157 legally in Montana?
BPC-157 is an unapproved drug that cannot be marketed for human use through ordinary channels. Montana's experimental treatment framework may create a supervised pathway, but that is separate from standard prescribing or retail sale.
Is compounded semaglutide allowed in Montana?
Compounded semaglutide can be made only for an identified patient under a valid prescription per Section 503A, and it is not FDA-approved, is not a generic, and is not evaluated by the FDA. Federal policy now limits GLP-1 compounding since the shortage resolved.
Is human growth hormone legal in Montana?
FDA-approved somatropin is legal only by physician prescription for approved indications. Federal law at 21 U.S.C. 333(e) makes unauthorized distribution a felony.
Sources
- PeptideLaws.com: Montana Peptide Laws & Regulations (retrieved 2026-09-21)
- Montana 69th Legislature: Senate Bill 535 (Authorized Print Version, Chapter 621) (retrieved 2026-09-21)
- FDA: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (retrieved 2026-09-21)
- FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (retrieved 2026-09-21)
- Zuber Lawler: Montana Law Expands Experimental Treatment Access (retrieved 2026-09-21)
Last researched: 2026-09-21.